ClinicalTrials.gg
Not yet recruitingNCT06038422Updated Sep 14, 2023

GTP Regimen in the Treatment of Refractory/Recurrent HLH

A Phase 3 interventional study of GTP regimen in Refractory, Recurrence and Hemophagocytic Lymphohistiocytosis, sponsored by Beijing Friendship Hospital. Not yet recruiting. Open to participants aged 1 Month and older. Per ClinicalTrials.gov, last updated 2023-09-14.

Primary conditionLymphohistiocytosis, HemophagocyticRegistry: RecurrenceReclassifiedWhy we changed it
Registry
Recurrence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lymphohistiocytosis, Hemophagocytic
Why
  1. Recurrence describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Lymphohistiocytosis, Hemophagocytic.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Beijing Friendship Hospital · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2024, 2 years 2 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
1 Month and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Lymphohistiocytosis, Hemophagocytic by Beijing Friendship Hospital — 7 open to participants now, 7 under way, 3 of them phase 3. Lymphohistiocytosis, Hemophagocytic · Beijing Friendship Hospital.

Planned enrollment
16th of 17
15 · median 30
Started
2023
with 4 others
Phase 3
9 of 21
2 open now
Registered
18th of 21
by date

Among the 21 studies in Lymphohistiocytosis, Hemophagocytic by Beijing Friendship Hospital, this one is the 16th largest by planned enrollment of the 17 interventional ones that give a count, is one of 5 that started in 2023, is one of 9 in phase 3, and was the 18th registered.

Lymphohistiocytosis, Hemophagocytic

111 studies on the registry are indexed under Lymphohistiocytosis, Hemophagocytic; 41 are open to participants now.

Browse Lymphohistiocytosis, Hemophagocytic studies →

Open to participants now

7 of the 21 studies in Lymphohistiocytosis, Hemophagocytic by Beijing Friendship Hospital are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 26 Lymphohistiocytosis, Hemophagocytic studies recruiting now, 14 (54%) set no upper age limit and 8 (31%) stop at 75 or younger; 15 take children under 18; 2 take healthy volunteers.

This study: 1 Month and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Lymphohistiocytosis, Hemophagocytic by Beijing Friendship Hospital, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn about efficacy and safety of GTP regimen in refractory/recurrent hemophagocytic lymphohistiocytosis. The main questions it aims to answer are:

  • Overall remission rate of GTP regimen in R/R HLH
  • Adverse effect of GTP regimen Participants will be treated with GTP regimen
Read the detailed description

Refractory/recurrent hemophagocytic lymphohistiocytosis will be treated with emapalumab combined with teniposide and methylprednisolone. Observed the overall response rate and side effects.

03

Conditions studied

  • Refractory
  • Recurrence
  • Hemophagocytic Lymphohistiocytosis

Browse trials for

04

In context

Lymphohistiocytosis, Hemophagocytic Reclassified

111 studies on the registry are indexed under Lymphohistiocytosis, Hemophagocytic; 41 are open to participants now.

This study's planned enrollment of 15 is below the median of 30 across 75 interventional studies indexed under Lymphohistiocytosis, Hemophagocytic.

Browse Lymphohistiocytosis, Hemophagocytic studies →

Lead sponsor

Beijing Friendship Hospital is the lead sponsor of 217 studies on the registry; 94 are open to participants now.

Compared within Lymphohistiocytosis, Hemophagocytic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
1 Month and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female patients ≥1 month of age with HLH
  2. Definitive diagnosis of HLH: meets the molecular diagnosis of pHLH or has a family history of HLH, or meets at least 5 of the 8 diagnostic criteria of HLH-2004.
  3. The investigators assessed the presence of /recurrent HLH disease. Patients must meet one of the following criteria assessed by the investigator:

    • Previous conventional HLH treatment did not respond.
    • The patients were not satisfied with the efficacy of conventional HLH treatment or their condition worsened.
    • HLH reactivation occurs. Reactivation is defined as: worsening of two or more HLH clinical and laboratory criteria (after initial remission).
  4. According to the researchers, the expected survival was more than 2 weeks.
  5. The is signed by the patient or his legal guardian (patients under 18 years), or by the patient's legally authorized representative.
  6. Women who are fertile are willing to use a highly effective method from the start of the study until 6 months after the end of the last course of treatment.

Exclusion criteria

Exclusion Criteria:

  1. There is active mycobacterium, histoplasma capsulatus, Salmonella, or leishmania infection.
  2. There is uncontrolled active gastrointestinal bleeding.
  3. The investigator believes that there are any serious comorbidities or any other conditions that make the patient unsuitable for treatment.
  4. A history of or hypersensitivity to any component of the drug in the study protocol, such as polysorbate.
  5. Had received the BCG vaccine within 12 weeks prior to screening.
  6. Have received live or attenuated vaccine (except BCG) within 4 weeks prior to screening.
  7. Pregnancy patients.
  8. Within 4 weeks prior to enrollment in this study, another concurrent clinical intervention study was enrolled.
  9. There is any condition or circumstance that the investigator believes may cause the patient to be unable to complete the study or to comply with study procedures or requirements.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    GTP regimen treated patients

    R/R HLH patients treated with GTP regimen

    Drug: GTP regimen

Interventions

  • DrugGTP regimen

    Refractory/recurrent hemophagocytic lymphohistiocytosis patients will be treated with GTP regimen (Emapalumab+Teniposide+Methylprednisolone)

07

What researchers measure

Primary outcomes

  1. ORR

    Overall remission rate

    Time frame: 1 year

08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2023; primary completion for Sep 2024, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2023
First posted
Sep 14, 2023
StartEst.
Sep 15, 2023
Primary completionEst.
Sep 15, 2024
CompletionEst.
Sep 15, 2025
Last update
Sep 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06038422
Responsible party
Zhao Wang (director of department, Beijing Friendship Hospital) — Principal investigator
First posted
Sep 14, 2023
Start date
Sep 15, 2023 (estimated)
Primary completion
Sep 15, 2024 (estimated)
Completion
Sep 15, 2025 (estimated)
Last update
Sep 14, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion